Merck, Samsung Bioepis to develop insulin glargine candidate for diabetes PBR Staff Writer Published 12 February 2014 Merck and Samsung Bioepis have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate, to treat patients with type 1 and type 2 diabetes.The company said that Phase III clinical trials in type 1 and type 2 diabetes will commence soon. Merck senior vice president of Diabetes, Global Human Health Matt Strasburger said the company seeks to collaborate with Samsung Bioepis on this insulin glargine candidate, as diabetes is a top priority for the company. "Merck is strengthening its leadership in diabetes through our own work and in collaboration with others, and this agreement will help build our portfolio across the spectrum of the disease," Strasburger said.Samsung Bioepis CEO Christopher Hansung Ko said, "This collaboration will bring better access to patients with diabetes worldwide."As part of the deal, the companies will collaborate on clinical development, regulatory filings and manufacturing. The deal builds on the agreement made by the two companies in February 2013 to develop and commercialize multiple biosimilar candidates. Samsung Bioepis is a joint venture between Samsung Biologics and Biogen, and it aims to develop affordable and high-quality biopharmaceutical and biosimilar products.
Posts
No comments:
Post a Comment